IXT-004

IXT-004 is an investigational dry powder inhalation therapy being developed by invoX Pharma for the treatment of asthma. The drug candidate utilizes the proprietary Softhaler® platform, a high-performance dry powder inhaler (DPI) technology designed to optimize drug delivery to the lungs with minimal inspiratory effort. While the specific active pharmaceutical ingredient and its molecular target have not been publicly disclosed, the program is part of invoX Pharma's respiratory pipeline, which focuses on leveraging advanced delivery systems for chronic pulmonary conditions. The Softhaler® technology is capable of delivering a variety of therapeutic modalities, including small molecules and potentially biological molecules such as peptides or antibodies.